PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

被引：14

作者：

Jia, Xiaoming ^{[1
]}

Al Rifai, Mahmoud ^{[1
]}

Saeed, Anum ^{[2
]}

Ballantyne, Christie M. ^{[1
]}

Virani, Salim S. ^{[1
,3
]}

机构：

[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[2] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA

[3] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX 77030 USA

来源：

VASCULAR HEALTH AND RISK MANAGEMENT | 2022年 / 18卷

关键词：

PCSK9; inhibitor; CVD prevention; lipids; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; PERIPHERAL ARTERY-DISEASE; 9; MONOCLONAL-ANTIBODY; COST-EFFECTIVENESS; DOUBLE-BLIND; ALIROCUMAB TREATMENT; LOWERS CHOLESTEROL; LDL CHOLESTEROL; REDUCING LIPIDS; AMG; 145;

D O I：

10.2147/VHRM.S275739

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

引用

页码：555 / 566

页数：12